Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Lindsey R. Baden , Hana M El Sahly , Brandon Essink , Lindsey R. Baden , Hana M El Sahly , Brandon Essink , Karen Kotloff , Sharon Frey , Rick Novak , David Diemert , Stephen A. Spector , Nadine Rouphael , C. Buddy Creech , John McGettigan , Shishir Khetan , Nathan Segall , Joel Solis , Adam Brosz , Carlos Fierro , Howard Schwartz , Kathleen Neuzil , Lawrence Corey , Peter Gilbert , Holly Janes , Dean Follmann , Mary Marovich , John Mascola , Laura Polakowski , Julie Ledgerwood , Barney S. Graham , Hamilton Bennett , Rolando Pajón , Conor Knightly , Brett Leav , Weiping Deng , Honghong Zhou , Shu Han , Melanie Ivarsson , Jacqueline Miller , Tal Zaks
2020 New England Journal of Medicine 10,252 citations

Abstract

The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
384
Issue
5
Pages
403-416
Citations
10252
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

10252
OpenAlex

Cite This

Lindsey R. Baden, Hana M El Sahly, Brandon Essink et al. (2020). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine , 384 (5) , 403-416. https://doi.org/10.1056/nejmoa2035389

Identifiers

DOI
10.1056/nejmoa2035389